• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New treatment developed to dramatically slow down the progression of blindness-causing retinal diseases

Bioengineer by Bioengineer
February 14, 2024
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The Korea Institute of Science and Technology (KIST) announced that Dr. Maesoon Im of the Brain Science Institute, together with Prof. Seung Ja Oh of Kyung Hee University and Prof. Kangwon Lee of Seoul National University, successfully incorporated anti-inflammatory drugs into a hydrogel to suppress inflammation in the retina and effectively deliver the drugs to the inflamed area.

Figure 1

Credit: Korea Institute of Science and Technology

The Korea Institute of Science and Technology (KIST) announced that Dr. Maesoon Im of the Brain Science Institute, together with Prof. Seung Ja Oh of Kyung Hee University and Prof. Kangwon Lee of Seoul National University, successfully incorporated anti-inflammatory drugs into a hydrogel to suppress inflammation in the retina and effectively deliver the drugs to the inflamed area.

Age-related macular degeneration and retinitis pigmentosa are incurable eye diseases that cause blindness due to the gradual damage of photoreceptor cells, which convert light into biological signals in the retina, the light-sensitive tissue at the back of the eye. Age-related macular degeneration is a condition that damages the macula, the central part of the retina, and is the number one cause of blindness in people over the age of 65. Retinitis pigmentosa, on the other hand, is a genetic disorder that causes gradual death in the photoreceptor cells in the retina and affects about 1 in 4,000 people worldwide, initially causing night blindness but eventually leading to vision loss.

Currently, there is no effective cure for either disease, and one of the treatments is to inject anti-inflammatory drugs into the eye to slow down the degree of retinal damage. However, these injections only work for as long as the drug remains in the eye, requiring patients to visit a clinic for intraocular injections every four to 12 weeks, depending on how long the effect of the drug lasts.

For the first time, the team utilized a substance that inhibits the inflammatory factor EZH2, which contributes to retinal degeneration, along with an anti-inflammatory agent. When mice with retinal degeneration were injected with the anti-inflammatory drug, the progression of retinal degeneration slowed down.

The researchers have successfully developed a hydrogel that slowly degrades upon encountering the enzyme cathepsin, which is typically overexpressed in inflammatory environments, to deliver anti-inflammatory drugs. When the team’s drug-loaded inflammation-responsive hydrogel was injected into the eyes of mice suffering from retinal degeneration, inflammatory factors in the retina were reduced to approximately 6.1%. The team also found that the protective effect on photoreceptor cells, which are known to be destroyed by retinal degeneration, was about four times higher than in the control group, effectively delaying vision loss.

Notably, the hyaluronic acid-based hydrogel, which has similar mechanical and optical properties to the vitreous humor of the eye, allows for different rates of hydrogel degradation in each patient, minimizing the need for repeated injections. This newly developed technology is expected to reduce the economic burden and the risk of accidents during outpatient visits for patients with difficulty in mobility due to visual impairment. Additionally, for patients in the early stages of symptoms, reducing the frequency of hospital visits can alleviate inconvenience in daily life.

“For future commercialization, we plan to digitize the amount of drug and hydrogel used, as well as the treatment period, according to the progression of the disease. We also intend to assess the long-term stability of the drug delivery system,” said Dr. Maesoon Im of KIST. “In addition to the retinal degenerative diseases, we will investigate inflammation levels in other retinal diseases to see if our inflammation-responsive drug delivery system would work on those conditions,” said Prof. Seung Ja Oh of Kyung Hee University.

###

KIST was established in 1966 as the first government-funded research institute in Korea. KIST now strives to solve national and social challenges and secure growth engines through leading and innovative research. For more information, please visit KIST’s website at https://eng.kist.re.kr/

This research was supported by the Ministry of Science and ICT (Minister Lee Jong-ho) through the KIST Major Project and Young and Mid-Career Researchers, the Excellent Young Researcher Support Project, the Brain Function Identification and Regulation Technology Development Project, and the Public Benefit Medical Technology Research Project of the Ministry of Health and Welfare (Minister Cho Kyu-hong). The research were published in the latest issue of the international journal ‘npj Regenerative Medicine‘ (IF 7.2, top 19.3% in JCR).



Journal

npj Regenerative Medicine

DOI

10.1038/s41536-023-00342-y

Article Title

Effective Protection of Photoreceptors Using an Inflammation-Responsive Hydrogel to Attenuate Outer Retinal Degeneration

Article Publication Date

14-Dec-2023

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Unraveling EMT’s Role in Colorectal Cancer Spread

August 2, 2025
Gut γδ T17 Cells Drive Brain Inflammation via STING

Gut γδ T17 Cells Drive Brain Inflammation via STING

August 2, 2025

Agent-Based Framework for Assessing Environmental Exposures

August 2, 2025

MARCO Drives Myeloid Suppressor Cell Differentiation, Immunity

August 2, 2025

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    39 shares
    Share 16 Tweet 10
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unraveling EMT’s Role in Colorectal Cancer Spread

Gut γδ T17 Cells Drive Brain Inflammation via STING

Agent-Based Framework for Assessing Environmental Exposures

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.